INTS
MaterialsIntensity Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving INTS Today?
No stock-specific AI insight has been generated for INTS yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
INTS News
20 articles- Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 7, 2026
- Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock NowYahoo Finance·May 1, 2026
- Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Apr 16, 2026
- Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare InnovationYahoo Finance·Apr 15, 2026
- Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate UpdateYahoo Finance·Mar 27, 2026
- Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the USYahoo Finance·Mar 24, 2026
- Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 StudyYahoo Finance·Mar 12, 2026
- Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price RequirementYahoo Finance·Mar 6, 2026
- Intensity Therapeutics Announces Reverse Stock SplitYahoo Finance·Feb 13, 2026
- Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic PrioritiesYahoo Finance·Jan 13, 2026
- All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to BuyYahoo Finance·Dec 15, 2025
- Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer SymposiumYahoo Finance·Dec 11, 2025
- Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price RequirementYahoo Finance·Dec 5, 2025
- Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer SymposiumYahoo Finance·Dec 4, 2025
- Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 6, 2025
- BC-Most Active StocksYahoo Finance·Oct 31, 2025
- Intensity Therapeutics stock up nearly 400% on solid tumour dataClinicaltrialsarena·Oct 31, 2025
- Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common StockYahoo Finance·Oct 31, 2025
- Trending tickers: Apple, Amazon, Netflix, Reddit and Intensity TherapeuticsYahoo·Oct 31, 2025
- Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science JournalYahoo Finance·Oct 30, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Intensity Therapeutics Inc
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.